VAL301

For Endometriosis

Discovery Optimisation Pre-clinical Phase 1 Phase 2

Small molecule, peptide, New Chemical Entity (NCE), VAL301 peptide re-purposed towards non-cancerous cell proliferation.

Mechanism of action: Inhibition of androgen activation of SRC kinase

Primary Indication: Endometriosis;

Developed in-house by ValiRx, under evaluation by an undisclosed Japanese Pharmaceutical Company

Published research: Pimping up Drugs Recovered, Superannuated and Under Exploited Drugs - An Introduction to the Basics of Drug Reprofiling: Suzanne J. Dilly, George S. Morris. Curr Drug Discov Technol. 2017 Jun; 14(2): 121–126.

Patents: PCT patent family application WO/2013/064830.

Granted and allowed patents: AU2017225015; CN104136082; EP2773427; RU2684315; US10023612; further patents pending.